Transitioning India to advanced image based adaptive brachytherapy: a national impact analysis of upgrading National Cancer Grid cervix cancer guidelines.

Access Activity-mapping Brachytherapy Cervix cancer

Journal

The Lancet regional health. Southeast Asia
ISSN: 2772-3682
Titre abrégé: Lancet Reg Health Southeast Asia
Pays: England
ID NLM: 9918419282806676

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 04 10 2022
revised: 05 02 2023
accepted: 03 05 2023
medline: 11 9 2023
pubmed: 11 9 2023
entrez: 11 9 2023
Statut: epublish

Résumé

High-dose-rate image guided brachytherapy (IGBT) for cervical cancer leads to improved local control and reduced toxicity and is a critical component of treatment. However, transition to IGBT requires capacity upscaling. An institutional activity mapping and national impact analysis of such a transition were undertaken to understand feasibility. Between September 2020 and March 2021, activity mapping was conducted in a high-volume centre that triaged cervical cancer patients for brachytherapy into four workflows; A: two-dimensional (2D) X-Ray point A-based intracavitary brachytherapy, B: CT point A-based intracavitary brachytherapy, C: MRI/CT-volume based intracavitary brachytherapy, D: MRI/CT volume-based intracavitary +/- interstitial brachytherapy. Clinical process time mapping was performed, and case scenarios for transition were modelled at the institutional and national levels based on available incidence and infrastructure levels. Treatment capacity changes were calculated, and potential strategies for workflow reorganisation were proposed. Eighty-four patients were included in the study. The total time taken for the workflows A, B, C, and D were 176 min (57-208), 224 min (74-260), 267 min (101-302), and 348 min (232-383), respectively. The transition from workflow A to D through sequential steps led to 35%, 49%, and 64% loss of treatment capacity in the index institution. Solutions such as 10-hour or 12-hour overlapping shifts increased treatment capacity by 25% and 50% and performing single implants and delivering multiple fractions increased capacity by 100%. Twenty-three Indian states and Union Territories are predicted to be able to transition to advanced workflows. For four Indian states, it may be detrimental considering the current infrastructure level, and eight Indian states lacked brachytherapy access. Further financial investment is required in the latter 12 states for transition to advanced workflows. Our study demonstrates that unplanned transition to IGBT can lead to treatment capacity loss and increase in waiting lists to access treatment. The proposed solutions of workflow reorganisation, using strategies such as single brachytherapy applicator implant and delivering multiple treatment fractions can improve access to treatment for women with cervix cancer in resource-strained and high patient-volume settings. We recommend state-wise solutions for the upscale from conventional 2D workflows to IGBT, subject to the availability of skilled personnel, infrastructure and training. Financial investments may be needed in some states to achieve this goal. International Atomic Energy Agency (IAEA) supported the salary of VH through project E33042 that focussed on implementation strategies of image guided brachytherapy.

Sections du résumé

Background UNASSIGNED
High-dose-rate image guided brachytherapy (IGBT) for cervical cancer leads to improved local control and reduced toxicity and is a critical component of treatment. However, transition to IGBT requires capacity upscaling. An institutional activity mapping and national impact analysis of such a transition were undertaken to understand feasibility.
Methods UNASSIGNED
Between September 2020 and March 2021, activity mapping was conducted in a high-volume centre that triaged cervical cancer patients for brachytherapy into four workflows; A: two-dimensional (2D) X-Ray point A-based intracavitary brachytherapy, B: CT point A-based intracavitary brachytherapy, C: MRI/CT-volume based intracavitary brachytherapy, D: MRI/CT volume-based intracavitary +/- interstitial brachytherapy. Clinical process time mapping was performed, and case scenarios for transition were modelled at the institutional and national levels based on available incidence and infrastructure levels. Treatment capacity changes were calculated, and potential strategies for workflow reorganisation were proposed.
Findings UNASSIGNED
Eighty-four patients were included in the study. The total time taken for the workflows A, B, C, and D were 176 min (57-208), 224 min (74-260), 267 min (101-302), and 348 min (232-383), respectively. The transition from workflow A to D through sequential steps led to 35%, 49%, and 64% loss of treatment capacity in the index institution. Solutions such as 10-hour or 12-hour overlapping shifts increased treatment capacity by 25% and 50% and performing single implants and delivering multiple fractions increased capacity by 100%. Twenty-three Indian states and Union Territories are predicted to be able to transition to advanced workflows. For four Indian states, it may be detrimental considering the current infrastructure level, and eight Indian states lacked brachytherapy access. Further financial investment is required in the latter 12 states for transition to advanced workflows.
Interpretation UNASSIGNED
Our study demonstrates that unplanned transition to IGBT can lead to treatment capacity loss and increase in waiting lists to access treatment. The proposed solutions of workflow reorganisation, using strategies such as single brachytherapy applicator implant and delivering multiple treatment fractions can improve access to treatment for women with cervix cancer in resource-strained and high patient-volume settings. We recommend state-wise solutions for the upscale from conventional 2D workflows to IGBT, subject to the availability of skilled personnel, infrastructure and training. Financial investments may be needed in some states to achieve this goal.
Funding UNASSIGNED
International Atomic Energy Agency (IAEA) supported the salary of VH through project E33042 that focussed on implementation strategies of image guided brachytherapy.

Identifiants

pubmed: 37694176
doi: 10.1016/j.lansea.2023.100218
pii: S2772-3682(23)00078-1
pmc: PMC10485789
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100218

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

SC received funding and VH received salary from International Atomic Energy Agency (IAEA) [funding as a part of Coordinated Research Project E33042]. SC is a consultant to Kortuc Pharmaceuticals (Japan) and received educational grants from Varian and Elekta. All authors declare no other conflicts of interest.

Références

World J Clin Oncol. 2022 Mar 24;13(3):209-218
pubmed: 35433294
Brachytherapy. 2022 Jan-Feb;21(1):43-48
pubmed: 34376368
J Glob Oncol. 2018 Jul;4:1-9
pubmed: 30085892
JAMA Oncol. 2018 Apr 01;4(4):506-513
pubmed: 29423520
Radiother Oncol. 2022 May;170:70-78
pubmed: 35259419
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):826-834
pubmed: 34146636
J Glob Oncol. 2019 Jun;5:1-5
pubmed: 31166825
Lancet Glob Health. 2023 Feb;11(2):e197-e206
pubmed: 36528031
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):88-94
pubmed: 29079120
J Contemp Brachytherapy. 2017 Apr;9(2):177-186
pubmed: 28533808
Front Oncol. 2014 Nov 25;4:315
pubmed: 25505730
Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):328-39
pubmed: 26549990
Tech Innov Patient Support Radiat Oncol. 2021 Oct 30;20:23-27
pubmed: 34765750
J Clin Oncol. 2018 Jun 1;36(16):1548-1555
pubmed: 29432076
JCO Glob Oncol. 2020 Jul;6:1063-1075
pubmed: 32673076
Gynecol Oncol. 2014 Nov;135(2):231-8
pubmed: 25172763
Brachytherapy. 2014 May-Jun;13(3):233-9
pubmed: 24559793
Radiother Oncol. 2006 Jan;78(1):67-77
pubmed: 16403584
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):95-96
pubmed: 29254783
Brachytherapy. 2019 Jul - Aug;18(4):445-452
pubmed: 30992185
Lancet Oncol. 2021 Apr;22(4):538-547
pubmed: 33794207
Radiother Oncol. 2019 Dec;141:123-129
pubmed: 31495516
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):608-617
pubmed: 29280456
J Med Phys. 2021 Oct-Dec;46(4):231-243
pubmed: 35261493
BMJ Open. 2022 Apr 6;12(4):e055765
pubmed: 35387819
Radiother Oncol. 2020 Jul;148:143-150
pubmed: 32387841
Indian J Cancer. 2018 Jan-Mar;55(1):45-49
pubmed: 30147092
Brachytherapy. 2022 Jan-Feb;21(1):49-54
pubmed: 34389265
Radiother Oncol. 2012 Jun;103(3):305-13
pubmed: 22633469
J Contemp Brachytherapy. 2019 Dec;11(6):527-533
pubmed: 31969910
J Glob Oncol. 2018 Jul;4:1-15
pubmed: 30085891
Indian J Med Res. 2021 Aug;154(2):375-382
pubmed: 35142654
Indian J Cancer. 2019 Oct-Dec;56(4):359-363
pubmed: 31607709
Brachytherapy. 2018 Sep - Oct;17(5):753-760
pubmed: 29844009
Brachytherapy. 2023 Mar-Apr;22(2):125-131
pubmed: 36585283
Phys Imaging Radiat Oncol. 2021 May 26;18:61-67
pubmed: 34258410

Auteurs

Varsha Hande (V)

Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Supriya Chopra (S)

Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Alfredo Polo (A)

Applied Radiation Biology and Radiotherapy Section, Division of Human Health, International Atomic Energy Agency, Vienna, Austria.

Prachi Mittal (P)

Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Satish Kohle (S)

Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Yogesh Ghadi (Y)

Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Jaahid Mulani (J)

Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Ankita Gupta (A)

Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Rajesh Kinhikar (R)

Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Jai Prakash Agarwal (JP)

Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Maharashtra, India.

Classifications MeSH